All questionsSpecific populations: Qulipta (atogepant) in preventive treatment of migraine6 questions · 2 sourcesPregnancy and breastfeedingIs Qulipta safe during pregnancy?“There are no adequate data on the developmental risk associated with the use of QULIPTA in pregnant women. In animal studies, oral administration of atogepant during the period of organogenesis (rats and rabbits) or throughout pregnancy and lactation (rats) resulted in adverse developmental effects (decreased fetal and offspring body weight in rats; increased incidence of fetal structural variations in rabbits) at exposures greater than those used clinically [see Data].” (opens the source at this quote in a new tab)CopyFlag“There is a pregnancy exposure registry that monitors outcomes in women who become pregnant while taking QULIPTA. Patients should be encouraged to enroll by calling 1-833-277-0206 or visiting http://empresspregnancyregistry.com.” (opens the source at this quote in a new tab)CopyFlag“The effect of QULIPTA on pregnancy has not been clinically evaluated.1” (opens the source at this quote in a new tab)CopyFlagCan you take Qulipta while breastfeeding?“Data from a lactation study in twelve healthy adult females indicate that atogepant is excreted in breast milk in low amounts. The estimated relative infant dose is approximately 0.19% of the maternal weight-adjusted dose, and the milk-to-plasma ratio is 0.08 (see Data). There are no data on the effects of atogepant on the breastfed infant or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QULIPTA and any potential adverse effects on the breastfed infant from QULIPTA or from the underlying maternal condition.” (opens the source at this quote in a new tab)CopyFlagPediatric useCan children or teenagers take Qulipta?“Safety and effectiveness in pediatric patients have not been established.” (opens the source at this quote in a new tab)CopyFlagSpecific populationsIs Qulipta safe for older adults (65 and over)?“Population pharmacokinetic modeling suggests no clinically significant pharmacokinetic differences between elderly and younger subjects. Clinical studies of QULIPTA did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be” (opens the source at this quote in a new tab)CopyFlag“cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.” (opens the source at this quote in a new tab)CopyFlagNote: The first passage ends at the foot of page 7 and the sentence continues on page 8 in the second passage.What is the Qulipta dose for kidney disease or dialysis?“The renal route of elimination plays a minor role in the clearance of atogepant [see Clinical Pharmacology (12.3)]. For episodic migraine, in patients with severe renal impairment (CLcr 15-29 mL/min) and in patients with end-stage renal disease (ESRD) (CLcr <15 mL/min), the recommended dosage of QULIPTA is 10 mg once daily; in patients with ESRD undergoing intermittent dialysis, QULIPTA should preferably be taken after dialysis [see Dosage and Administration (2.2)]. For chronic migraine, use of QULIPTA in patients with severe renal impairment and in patients with ESRD is not recommended. No dose adjustment is recommended for patients with mild or moderate renal impairment.” (opens the source at this quote in a new tab)CopyFlagCan Qulipta be used with liver disease (hepatic impairment)?“No dose adjustment of QULIPTA is recommended for patients with mild or moderate hepatic impairment. Avoid use of QULIPTA in patients with severe hepatic impairment [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3)].” (opens the source at this quote in a new tab)CopyFlag“In patients with pre-existing mild (Child-Pugh Class A), moderate (Child-Pugh Class B), or severe (Child-Pugh Class C) hepatic impairment, the total atogepant exposure was increased by 24%, 15%, and 38%, respectively. Due to a potential for liver injury in patients with severe hepatic impairment, avoid use of QULIPTA in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].” (opens the source at this quote in a new tab)CopyFlag